GlobalData’s senior medical analyst says the ban will add to a downward trend for Illumina in the Chinese market.

Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...

The MiSeq desktop sequencer offers low throughput flowcells and long read lengths. It is best for small whole-genome sequencing, targeted gene sequencing, metagenomics, and CRISPR validation. The ...

Illumina and next-gen sequencing (NGS) are synonymous. But to anyone paying attention, the company’s recent emphasis on multiomics has been hard to miss. Indeed, the company has launched both ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

The funding will be used to support the commercial rollout of Element’s benchtop instrument for next-generation sequencing (NGS), Aviti, which is a competitor to Illumina technology, like its ...

The advent of next-generation sequencing has made possible genome analysis at previously unattainable depth. Roche, Illumina and Life Technologies, among others, have developed well-established ...

The new omics solutions surpass industry standards for scale, accuracy, and reliability because t Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based ...

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...

Medical Device Network · JHVEPhoto via Shutterstock. China has banned the import of Illumina’s next-generation sequencing (NGS) sequencers as part of retaliatory measures against fresh tariffs ...